Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
Top Cited Papers
- 20 March 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (9), 1182-1189
- https://doi.org/10.1200/jco.2010.29.9024
Abstract
Purpose Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care. This study evaluated the efficacy and tolerability of pralatrexate...This publication has 21 references indexed in Scilit:
- Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib inIn vitroandIn vivoModels of T-Cell Lymphoid MalignanciesClinical Cancer Research, 2010
- Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targetsCritical Reviews in Oncology/Hematology, 2009
- Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell MalignanciesJournal of Clinical Oncology, 2009
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- Management of peripheral T-cell non-Hodgkin's lymphomaCurrent Opinion in Oncology, 2007
- Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphomaBritish Journal of Haematology, 2006
- The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's LymphomaClinical Cancer Research, 2006
- Non-Hodgkin lymphoma: an updateThe Lancet Oncology, 2004
- Activity of a Novel Anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene ExpressionLeukemia & Lymphoma, 2003
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989